Ayala Pharmaceuticals, Inc.
Other OTCTotal Valuation
Ayala Pharmaceuticals, Inc. carries a market capitalization of 25.71M, placing it among publicly traded companies globally. Its enterprise value stands at 7.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 25.71M |
| Enterprise Value | 7.77M |
Share Statistics
Ayala Pharmaceuticals, Inc. currently has 14.82M shares outstanding.
| Shares Outstanding | 14.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.18, and the price-to-book ratio stands at -0.06.
| PE Ratio | N/A |
| PS Ratio | 12.18 |
| PB Ratio | -0.06 |
| P/TBV Ratio | -7.67 |
| P/FCF Ratio | -0.24 |
| P/OCF Ratio | -0.24 |
Enterprise Valuation
| EV / Sales | 11.23 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Ayala Pharmaceuticals, Inc. maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -159.33, indicating conservative leverage, while an interest coverage ratio of -889.33 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.51 |
| Quick Ratio | 0.43 |
| Debt / Equity | -159.33 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -889.33 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -155.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 584,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ayala Pharmaceuticals, Inc.'s stock has gained approximately 1911.83333% over the past 52 weeks. The 50-day moving average sits at 0.23, while the 200-day moving average is 0.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1911.83333% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.10 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ayala Pharmaceuticals, Inc. generated 692,000.00 in revenue and converted that into -37.91M in net income, yielding earnings per share of -5.40. EBITDA reached -37.35M, while operating income came in at -37.51M.
| Revenue | 692,000.00 |
| Gross Profit | 90,000.00 |
| Operating Income | -37.51M |
| Pretax Income | -37.32M |
| Net Income | -37.91M |
| EBITDA | -37.35M |
| EBIT | -37.51M |
| Earnings Per Share (EPS) | -5.40 |
Balance Sheet
Ayala Pharmaceuticals, Inc. holds 2.41M in cash and equivalents against 1.75M in total debt, resulting in a net debt position of -2.41M. Total book value stands at -149.15M, with working capital of -3.01M providing operational flexibility.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 1.75M |
| Net Debt | -2.41M |
| Equity (Book Value) | -149.15M |
| Book Value Per Share | -21.23 |
| Working Capital | -3.01M |
Cash Flow
Ayala Pharmaceuticals, Inc. produced -34.51M in operating cash flow over the past twelve months.
| Operating Cash Flow | -34.51M |
| Capital Expenditures | N/A |
| Free Cash Flow | -34.51M |
| FCF Per Share | -4.91 |
Margins
Ayala Pharmaceuticals, Inc. operates with a gross margin of 13.01, reflecting its pricing power and cost economics. The operating margin of -5,421.10 and net profit margin of -5,478.03 provide insight into operational efficiency.
| Gross Margin | 13.01 |
| Operating Margin | -5,421.10 |
| Pretax Margin | -5,393.64 |
| Profit Margin | -5,478.03 |
| EBITDA Margin | -5,397.69 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.22 |
| FCF Yield | -409.43 |
Stock Splits
Ayala Pharmaceuticals, Inc.'s most recent stock split took place on June 6, 2022 with a 80:1 split ratio.
| Last Split Date | 6/6/2022 |
| Split Ratio | 80:1 |
Scores
Ayala Pharmaceuticals, Inc. posts an Altman Z-Score of -42.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -42.62 |